Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Gastrointestinal Stromal Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Chronic-Phase 6Leukemia 6Blast Crisis 5Sarcoma 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Accelerated Phase 3Carcinoma, Ovarian Epithelial 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Meningioma 2Melanoma 2Leukemia, Biphenotypic, Acute 2Fibrosarcoma 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Breast Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Seminoma 1Sarcoma, Synovial 1

Interventions

ruxolitinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hypereosinophilic Syndrome × Imatinib Mesylate × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡